SCHEMBL7101154

SCHEMBL7101154

COC(=O)[C@@H](N)Cc1cn(Cc2ccc(Cl)cc2Cl)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 7/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
AKT3 Q9Y243 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.38
RECQL P46063 1/20 0.37
JAK2 O60674 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6499762 0.86 KDM2B (0.41) MEN1KMT2AGAANPC1ALDH1A1
Hydrochloric Acid SCHEMBL6529050 0.84 FNTA (0.40) CYP3A4CYP2C9ALDH1A1LMNA
Hydrochloric Acid SCHEMBL6531456 0.82 SMN1; SMN2 (0.41) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7099218 0.82 PHF8 (0.40) CYP3A4CYP2C9ALDH1A1LMNATP53
SCHEMBL7098286 0.81 ALDH1A1 (0.38) CYP3A4CYP2C9MEN1KMT2AALDH1A1
SCHEMBL7103438 0.81 SMN1; SMN2 (0.45) AKT3MEN1KMT2AGAANPC1
SCHEMBL6527840 0.80 CDK5 (0.47) CYP3A4CYP2C9
SCHEMBL6069460 0.80 CDK5 (0.47) CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL7356305 0.79 CDK5 (0.46) CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL6527843 0.79 CDK5 (0.46) CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991619-B1 INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2003-09-10 EP disclosed
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2003-07-10 US disclosed
EP-0991619-A1 INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2000-04-12 EP disclosed
WO-1998058902-A1 INHIBITORS OF α4β1MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion VCAM1, ICAM1, ITGB1 HDAC8 2950/4885CYP3A4 1685/4885CYP2C9 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.